Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Clinical Laserthermia Systems ABFRA:LS60 -3.55%41 Equity-to-Asset is 0.72 as of Jun. 2026, which is 3% above its 10-year median of 0.70. GuruFocus rates FRA:LS60 with a GF Score™ of 41/100 and a GF Value™ of €0.21 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 852 Medical Devices & Instruments companies, Clinical Laserthermia Systems AB ranks better than 62.91% on this metric.
The historical rank and industry rank for Clinical Laserthermia Systems AB's Equity-to-Asset or its related term are showing as below:
FRA:LS60'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.27 Med: 0.7 Max: 0.93
Current: 0.72
During the past 13 years, the highest Equity to Asset Ratio of Clinical Laserthermia Systems AB was 0.93. The lowest was -0.27. And the median was 0.70.
FRA:LS60's Equity-to-Asset is ranked better than 62.91% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 0.645
vs FRA:LS60: 0.72
Clinical Laserthermia Systems AB (FRA:LS60) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Clinical Laserthermia Systems AB Equity-to-Asset Related Terms
Clinical Laserthermia Systems AB Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clinical Laserthermia Systems AB Equity-to-Asset Chart
FRA:LS60 vs ABT, SYK, MDT: Equity-to-Asset Comparison
For the Medical Devices subindustry, Clinical Laserthermia Systems AB's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinical Laserthermia Systems AB Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Clinical Laserthermia Systems AB's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Clinical Laserthermia Systems AB's Equity-to-Asset falls into.
Clinical Laserthermia Systems AB Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clinical Laserthermia Systems AB (FRA:LS60) has a Equity-to-Asset of 0.72 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Clinical Laserthermia Systems AB and its competitors. This is near median its historical median of 0.70. According to the industry distribution chart, Clinical Laserthermia Systems AB ranks #316 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 37.1%.
Is Clinical Laserthermia Systems AB's Equity-to-Asset too high?
Clinical Laserthermia Systems AB's current Equity-to-Asset of 0.72 is near median its 10-year median of 0.70. The Medical Devices & Instruments industry median Equity-to-Asset is 0.65. Clinical Laserthermia Systems AB's value of 0.72 is 11.6% above this industry median. Based on the distribution chart, Clinical Laserthermia Systems AB ranks #316 out of 852 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Clinical Laserthermia Systems AB has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Clinical Laserthermia Systems AB's Equity-to-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Clinical Laserthermia Systems AB ranks #316 out of 852 companies for Equity-to-Asset. This puts Clinical Laserthermia Systems AB in the upper half of its industry. The industry median Equity-to-Asset is 0.65. Clinical Laserthermia Systems AB's value of 0.72 is 11.6% above this benchmark. While the company's 10-year median is 0.70 vs. the industry median of 0.65, Clinical Laserthermia Systems AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.65, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clinical Laserthermia Systems AB's current Equity-to-Asset of 0.72 is 11.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Clinical Laserthermia Systems AB and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clinical Laserthermia Systems AB's current Equity-to-Asset is 0.72, which is near median its own 10-year median of 0.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinical Laserthermia Systems AB stock overvalued right now?
Based on GuruFocus' analysis, Clinical Laserthermia Systems AB (FRA:LS60) is currently considered Possible Value Trap. The stock's GF Value™ is €0.21, compared to a current price of €0.11 — trading 45.6% below its estimated fair value. The current Equity-to-Asset is 0.72, which is near median its 10-year median of 0.70 and 11.6% above the Medical Devices & Instruments industry median of 0.65. Clinical Laserthermia Systems AB's overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Clinical Laserthermia Systems AB (FRA:LS60), the current Equity-to-Asset is 0.72 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clinical Laserthermia Systems AB (FRA:LS60) Overvalued in 2026?
Based on GuruFocus' analysis, Clinical Laserthermia Systems AB stock appears to be undervalued.
The current stock price of €0.11 is trading 45.6% below its estimated GF Value™ of €0.21.
GuruFocus considers Clinical Laserthermia Systems AB to be Possible Value Trap.
Key valuation signals for FRA:LS60:
Equity-to-Asset: 0.72 (near median its 10-year median of 0.70)
GF Value™: €0.21 vs. price of €0.11 (45.6% below fair value)
Industry Position: 11.6% above the Medical Devices & Instruments median (#316 of 852)
No single metric tells the full story. See the FRA:LS60 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clinical Laserthermia Systems AB develops and sells single-use products used during each treatment procedure of treatment of solid tumors cancers. Its products include Thermal Therapy System, Mobile Laser Unit, Laser Applicator Non-cooled and Tissue Temp Probe.
41GF Score
Get the complete analysis for FRA:LS60
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LS60 has been successfully added to your 
